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Summary
Patients with haematological malignancies are at risk for invasive fungal diseases (IFD). A survey 
was conducted in all Dutch academic haematology centres on their current diagnostic, prophy-
lactic and therapeutic approach towards IFD in the context of azole-resistance. In all 8 centres, a 
haematologist and microbiologist filled in the questionnaire that focused on different subgroups 
of haematology patients. Fungal prophylaxis during neutropaenia was directed against Candida 
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1  | INTRODUC TION
Invasive fungal disease (IFD) occur in 5%- 40% of patients with hae-
matological malignancies. Approximately 95% of the IFD are caused 
by Aspergillus and Candida species.1 IFD is associated with a very sig-
nificant morbidity and mortality that is explained by the difficulties 
in diagnosing IFD rapidly.1 In addition, the presence of an IFD leads 
to a delay in subsequent anti- leukemic therapy, and therefore also 
indirectly affects the outcome of the patient.2
Antifungal prophylaxis prevent IFD during acute myeloid leu-
kaemia (AML) therapy or during graft- versus- host disease (GVHD). 
These benefits have to be weighed against risks of drug toxicity, in-
teractions, selection of resistance and costs. Different opinions on 
the preferred antifungal strategy in these patients exist and the ap-
proach varies considerably from institution to institution.
Over the last 10 years resistance of A. fumigatus against triazoles, 
has become a significant problem in the Netherlands but has recently 
also been reported in other countries.3-5 Triazole- resistance can de-
velop through long- term azole therapy in patients with chronic pul-
monary aspergillosis. However, the selection of tri- azole resistance in 
the environment by the use of azole fungicides is far more important. 
This in agreement with the observation that the majority of triazole- 
resistant A. fumigatus strains contain the environmental TR34/L98H 
or the TR46/Y121F/T289A mutation pattern in their Cyp51A gene.
6 
This gene encodes for the target enzyme of triazoles.7 Infections with 
a triazole- resistant A. fumigatus result in a high mortality and the best 
diagnostic and treatment approach is uncertain.5,8 We conducted a 
survey on fungal diagnostics, antifungal prophylaxis and treatment in 
all Dutch academic haematology centres. The survey facilitated the 
development of a consensus approach towards the management of 
invasive aspergillosis (IA) in a context of rising azole-resistance.
2  | MATERIAL S AND METHODS
A questionnaire was sent to a haematologist and a microbiolo-
gist with special interest in supportive care and medical mycology 
respectively and both parties were asked to answer as a team for 
their centre. The questionnaire focused on (i) primary prophylaxis 
during AML chemotherapy, during allogeneic hematopoietic stem 
cell transplantation (allo- HSCT) and at the time of GVHD. (ii) How 
was screened for IFD and which diagnostic tests were performed. 
(iii) The current antifungal treatment for different clinical scenar-
ios. The results were processed and during a consensus meeting 
the protocol for The Azole-Resistance MANagement (AzoRMan) 
Study was developed and implemented.
3  | RESULTS
3.1 | Prophylaxis
3.1.1 | Prophylaxis directed against Candida
Fluconazole is given during neutropaenia of >10 days in 4/8 centres 
at very different dosages and amphotericin B oral suspension was 
used in 2 (Table 1). One centre also uses amphotericin B lozenge. 
One centre starts fluconazole when surveillance cultures grow 
Candida. If surveillance cultures show Candida species resistant 
to fluconazole, some centres switch to amphotericin B suspension 
and one centre adds amphotericin B suspension to fluconazole. 
Finally, one centre stops fluconazole and no other prophylaxis is 
initiated.
3.1.2 | Mould- active prophylaxis
Only one centre applies mould- active prophylaxis (itraconazole) 
during chemotherapy induced neutropaenia of >10 days and during 
myeloablative allo- HSCT. Therapeutic drug monitoring of itracona-
zole is performed and when no effective plasma concentrations are 
reached, a switch to voriconazole is made. In another centre nebu-
lised liposomal amphotericin B (L- AmB) at 15 mg QD, twice weekly 
is used for this purpose. All centres start mould- active prophylaxis 
when corticosteroids are given for GVHD but the drugs of choice 
differ (Table 1).
and consisted of fluconazole and/or amphotericin B suspension. Mould- active prophylaxis was 
given to acute myeloid leukaemia patients during chemotherapy in 2 of 8 centres. All centres 
used azole prophylaxis in a subset of patients with graft- versus- host disease. A uniform approach 
towards the diagnosis and treatment of IFD and in particular azole- resistant Aspergillus fumigatus 
was lacking. In 2017, all centres agreed to implement a uniform diagnostic and treatment algorithm 
regarding invasive aspergillosis with a central role for comprehensive diagnostics and PCR- based 
detection of azole-resistance. This study (DB- MSG 002) will re- evaluate this algorithm when 280 
patients have been treated. A heterogeneous approach towards antifungal prophylaxis, diagno-
sis and treatment was apparent in the Netherlands. Facing triazole- resistance, consensus was 
reached on the implementation of a uniform diagnostic approach in all 8 centres.
K E Y W O R D S
azole-resistance, IFD, invasive aspergillosis, management
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3.2 | Diagnosis
3.2.1 | Diagnostic procedures
A chest CT is routinely performed in all centres after 3 to 5 days of 
neutropenic fever without an infectious focus despite antibiotic ther-
apy (Table 2). When the chest CT scan shows pulmonary infiltrates a 
broncho- alveolar lavage (BAL) with galactomannan (GM) detection and 
fungal culture is performed in all centres (if clinically feasible). Twice 
weekly serum GM monitoring as a screening tool is performed in one 
centre only. Two centres perform an Aspergillus DNA PCR on BAL rou-
tinely; in one centre this is done only when BAL GM is positive or when 
an EORTC compatible radiological finding is suggestive of an IFD.
3.2.2 | Susceptibility testing
Different Aspergillus susceptibility testing methods are used: 
VIPcheck™ or Etest followed by confirmation with testing ac-
cording to the European Committee on Antibiotic Susceptibility 
Testing (EUCAST) method when resistance is suspected based 
on the screening assay (Table 3). The EUCAST method is op-
erational in the mycology reference laboratory (RefLab). 
Resistance screening is done in all but one centre with a 4- 
well plate (VIPcheck™) in which three of the four wells contain 
agar supplemented with an azole (voriconazole, itraconazole 
and posaconazole) and the fourth functions as a growth con-
trol. The other centre uses the Etest (bioMérieux) for resistance 
TABLE  1 Prophylactic strategies used against Candida and Aspergillus
Antifungal agent Dosage Number of centres
Candida prophylaxis during longstanding 
chemotherapy- induced neutropaenia
Fluconazole 50 mg/24 h 1
200 mg/24 h 2
400 mg/24 h 1
Amphotericin B suspension 500 mg/6 h 2
200 mg/12 h 1
Fluconazole when surveillance 
cultures grow Candida
1
Anti- mould prophylaxis in AML/MDS/AlloTx 
during longstanding chemotherapy- induced 
neutropaenia
Itraconazole suspension Start with 200 mg bid, dose 
increased based on TDM results
1
L- AmB aerosols 15 mg twice weekly 1
None 6
AlloTx with GVHD treated with systemic 
corticosteroids
Itraconazole Start with 200 mg bid, dose 
increased based on TDM results
1
2,5 mg/kg/12 h 1
Voriconazole 200 mg/12 h 1
Posaconazole 300 mg/24 h tablets 5
AlloTx, Allogeneic stem cell transplantation; AML, Acute Myeloid Leukaemia; GVHD, Graft- versus- Host disease; MDS, Myelodysplastic syndrome; 
TDM, Therapeutic Drug Monitoring. L- AmB, liposomal amphotericin- B.
Diagnostic procedure Possibilities Nr of centres




Chest CT- scan when 3- 5 days neutropaenic 




Bronchoscopy with BAL (when no evident 
cause for infiltrative lesions on imaging)
Yes 8
No 0




Aspergillus species PCR on BAL fluid Yes, always 2
Yes, if GM is positive 1
No 5
BAL, Bronchoalveolar lavage; GM, Galactomannan; FUO, Fever of unknown origin; IFD, Invasive 
Fungal Diseases.
TABLE  2 Diagnostic strategies used in 
patients at risk for or suspected of having 
an IFD
     |  659SCHAUWVLIEGHE Et AL.
screening. Simultaneous to the screening test, 4 centres send 
the Aspergillus strain directly to the RefLab for MIC testing. PCR 
testing for the presence of TR34 and TR46 directly on cultured 
A. fumigatus colonies is performed on- site in 4 centres to speed 
up resistance detection. A PCR- based resistance assay is per-
formed directly on BAL in 3 centres. For this purpose, a commer-
cially available qPCR (AsperGenius®) or an in- house PCR is used. 
One centre sends BAL samples to the RefLab for PCR testing.
3.3 | Treatment
Suspected invasive fungal infection:
All centres use voriconazole as the initial treatment for patients in a 
respiratory stable condition suspected of having an IFD while wait-
ing for the microbiological tests (Table 4). One centre frequently 
uses posaconazole as well and another centre with a high local 
azole-resistance prevalence prefers L- AmB if the patient is very ill. 
The feasibility of BAL fluid sampling is the decisive factor in another 
centre to guide therapy and voriconazole is given if a BAL is obtained 
and therefore, the detection of azole-resistance becomes more 
likely. If BAL is not feasible, this centre gives L- AmB as antifungal.
Proven or probable IA
Voriconazole is the treatment of choice for all centres when a 
BAL- GM assay is positive in a respiratory stable patient and the le-
sions on chest CT are not widespread, fungal culture remains neg-
ative and no susceptibility PCR is performed or the test was not 
successful. In the same clinical situation with a patient in respiratory 
distress or with extensive pulmonary infiltrates, five centres would 
still start voriconazole. Two centres would start L- AmB and one cen-
tre posaconazole.
Proven or probable IA and documented voriconazole 
resistance
If voriconazole resistance is demonstrated with one of the pheno-




Two centres do not perform therapeutic drug monitoring (TDM). 
Two centres do TDM when toxicity or treatment failure is suspected. 
The other centres routinely perform TDM.
3.4.2 | Posaconazole
Three centres always perform TDM and two centres do not. The 
other three centres perform TDM on indication only.
3.5 | Triazole resistance data
In 2016, A. fumigatus isolates from 784 clinical patients were screened 
for triazole resistance using a 4- well agar plate (VIPcheck™). Isolates 
that grew on the triazole- containing agar have a high probability of 
resistance and were sent to the Reflab for phenotypic and genotypic 
characterisation. 101 isolates (12.9%) were triazole- resistant, which 
TABLE  3 Diagnostic tests done on BAL fluid samples
Susceptibility assay Possibilities Nr of centres




Sends Aspergillus strain directly to RefLab
Phenotypic azole-resistance testing (EUCAST) of 
cultured Aspergillus strains
Directly sent to RefLab for EUCAST 
testing
4
Send to RefLab only if VIP™ screening is 
positive
2
Send to RefLab only if E- test is positive 1
EUCAST testing on site=RefLab 1
Testing for RAM on cultured Aspergillus strains Yes, in- house 4
Yes, not in- house 1
No 3
Testing for RAM (CYP51A) directly on BAL fluid Yes 2
No 4
On indication (if BAL culture is negative 
and patient is not doing clinically well)
1
Sends BAL sample to the RefLab 1
EUCAST, The European Committee on Antimicrobial Susceptibility Testing; GM, Galactomannan; VIP™ testing, resistance assay (explanation: see text); 
RAM, Resistance associated mutations (TR34/L98H, TR53, and TR46/Y121F/T289A); RefLab, National mycology reference laboratory in Nijmegen (The 
Netherlands); BAL, Broncho- alveolar lavage.
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was higher than 2014 (7.2%) and 2015 (10.7%). In individual centres, 
resistance ranged from 9.5% to 20.5%.6 Recently, a nationwide Dutch 
cohort study reported data from 144 patients with influenza pneumo-
nia admitted to all 8 University Intensive Care Units. 23 patients (16%) 
were diagnosed with influenza- associated invasive aspergillosis and 
triazole resistance was reported in 29% of those with a positive A. fu-
migatus culture.9 The clinical relevance of triazole resistance was also 
described in another recent study in which a multiplex real- time PCR 
test (AsperGenius© assay) was performed on BAL samples from 201 
patients. This qPCR allows the simultaneous detection of Aspergillus 
species and identification of the most common mutations in the A. fu-
migatus Cyp51A conferring resistance by using melting curve analysis. 
In 11 of the 68 patients in which the resistance PCR could be success-
fully performed, the TR34/L98H or TR46/T289A/Y121F resistance 
pattern was documented. More importantly, the detection of resist-
ance correlated with voriconazole treatment failure.8
4  | DISCUSSION
4.1 | Prophylaxis directed at Candida
The European Conference on Infections in Leukaemia (ECIL) 5 guide-
lines on antifungal prophylaxis recommends fluconazole (400 mg 
q24 h) when the mould infections are rare and a mould- directed diag-
nostic approach is in place (B- I).10 The latter is the case in all centres 
that were surveyed but the dose of fluconazole varies among cen-
tres and is generally lower than was used in most randomised trials 
(400 mg q24 h).11-15 Some studies suggest that lower doses may suf-
fice.16 Three centres use oral amphotericin B as primary prophylaxis 
and in others oral amphotericin B is given on top of fluconazole if 
surveillance cultures remain positive. In a pooled analysis of oral 
fluconazole vs amphotericin B no significant advantage of either of 
the two drugs was observed. Data on the efficacy of prophylactic 
amphotericin B are scarce.17 According to the EBMT, fluconazole is 
the drug of choice for the prophylaxis of invasive candidiasis before 
engraftment in allo- HSCT recipients, and may be started at the be-
ginning or after the end of the conditioning regimen (A- I).18
4.2 | Mould- active prophylaxis
The advantage of primary mould- active prophylaxis with posacon-
azole was shown in two randomised trials.13,14 The Dutch guide-
line on antifungal management as well as the ECIL- 5 guideline 
recommends posaconazole for primary prophylaxis (A- I) when the 
incidence of mould infections is high.10,19 Firm criteria for what con-
stitutes `high risk` are lacking but it has been proposed that sub-
populations with >8%- 10% fall into this category. Unfortunately, 
reliable data on the local prevalence of mould infections are often 
lacking.20 One centre administers aerosolised L- AmB twice weekly 
for the prevention of IFD in AML patients undergoing intensive 
chemotherapy. Its efficacy and cost- effectiveness have been dem-
onstrated in a single- centre randomised placebo- controlled trial 
and an observational study.21,22 One centre uses itraconazole as 
antifungal prophylaxis. A major concern of itraconazole is its poor 
gastrointestinal tolerance and CYP3A4 inhibitory properties. Both 
the ECIL- 5 and the IDSA guidelines give moderate recommenda-
tions against its use.10,23 All centres use a diagnostic protocol that 
includes a lung CT after three to 5 days of fever despite antibiotic 
TABLE  4 Treatment of invasive aspergillosis
Presentation Clinical condition Treatment options Nr of centres
Chest CT: suspected IFD but microbiological 
results pending
Respiratory and clinically stable Voriconazole 8
Respiratory and clinically instable Voriconazole 6
L- AmB 1
+BAL possible Voriconazole 1
+BAL impossible L- AmB
BAL GM pos, Culture/PCR neg Respiratory and clinically stable Voriconazole 8
Critically ill Voriconazole 5
L- AmB 2
Posaconazole 1
Resistance detected by culture or PCR Respiratory and clinically stable/instable L- AmB 8
TDM voriconazole No 2
Sometimes* 2
Always 4
TDM posaconazole No 2
Sometimes* 3
Always 3
BAL, Bronchoalveolar lavage; Resp, Respiratory; L- AmB, liposomal amphotericin- B; IFD, Invasive Fungal Diseases; PCR, Polymerase Chain Reaction; 
GM, Galactomannan; TDM, Therapeutic Drug Monitoring; +BAL possible/impossible: BAL sampling was possible/impossible; *Sometimes, when toxic-
ity or therapeutic failure is suspected.
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therapy and proceed to BAL sampling when infiltrates are docu-
mented. Indeed, a survival benefit of azole prophylaxis compared 
with a diagnostic- driven approach has not been convincingly 
shown and so both continue to be reasonable strategies.
4.3 | Mould- active prophylaxis in GVHD
Antifungal prophylaxis has been established as standard of care 
after allo- HSCT with grade II or higher GVHD, but issues concern-
ing drug- drug interactions and factors compromising bioavailability 
have to be considered. Ullman et al. performed a randomised trial in 
which fluconazole and posaconazole oral solution were compared as 
fungal prophylaxis in patients with GVHD. Posaconazole prevented 
IA and resulted in lower numbers of deaths related to IFD although 
the overall mortality did not differ.14 All centres administer azole 
prophylaxis (4 posaconazole, 2 voriconazole, 2 itraconazole) to pa-
tients with GVHD of grade II or higher in accordance with ECIL- 5 
recommendations in which an A- I recommendation is given for posa-
conazole and a B- I to itraconazole and voriconazole.10
4.4 | Diagnosis of IA
Pulmonary imaging with high- resolution CT (HRCT) was shown to 
accelerate and improve the diagnosis of IA.23 The IDSA guideline ad-
vocates imaging with chest CT when a patient is suspected to have 
IA. IDSA guidelines also encourage BAL since signs, symptoms or 
imaging by itself are often aspecific. All centres use HRCT and BAL 
as the standard diagnostic procedure. Serum GM monitoring has a 
moderate sensitivity of ±70% but is insensitive in non- neutropenic 
patients and the specificity has varied between studies.23,24 Only 
one centre routinely monitors serum GM in patients with prolonged 
neutropaenia. All centres measure BAL- GM and Aspergillus DNA 
PCR is performed in 3 centres on BAL fluid samples). The clinical im-
plementation of PCR- based diagnosis was debated, though not rec-
ommended for routine clinical practice in the 2016 IDSA guidelines 
as few assays have been standardised and well validated.23
4.5 | Susceptibility testing
Azole-resistance was rare in The Netherlands before the year 2000 
but its prevalence has continued to increase since then.25 It is cur-
rently based on a limited number of resistance- associated mutations 
(RAMs) in the cyp51A- gene (TR34/L98H, TR53, and TR46/Y121F/
T289A) and is most likely caused by the environmental use of azole 
fungicides.7,26,27 The TR34/L98H and TR46/Y121F/T289A accounted 
for 83% of resistance mutations in 2016.6 IDSA guidelines do not 
recommend standard susceptibility testing but these guidelines can-
not be applied to The Netherlands.23,28 Case series indicate that IA 
caused by azole- resistant Aspergillus, is associated with a very high 
mortality.5,8 The diagnostic tools used for the detection of azole-
resistance vary from centre to centre. Most perform agar- based 
screening assays for resistance (VIPcheck™ testing). Phenotypic 
azole-resistance testing according to the EUCAST method is 
performed by the National mycology reference laboratory only 
(RefLab). Four centres directly send Aspergillus strains to the RefLab 
and three await the result of the screening assay.
Only very recently, the clinical validity and relevance of PCR- 
based susceptibility testing on BAL was demonstrated and may 
explain the limited uptake of resistance detection by PCR at the 
time of the survey. The AsperGenius® qPCR is a multiplex PCR 
and can detect the presence of Aspergillus DNA and in addition 
detect the 2 mutations described above.8,29 In a recent study the 
diagnostic performance was evaluated on BAL- samples in 201 pa-
tients.8,29 The Aspergillus BAL qPCR, had a sensitivity of 89% and a 
specificity of 89% and was able to detect A. fumigatus that carried 
resistance- associated mutations (RAM) in the majority of patients, 
even in culture- negative BAL. Furthermore, this study showed that 
response to voriconazole therapy, when given to patients infected 
with a resistant A. fumigatus was poor.8
4.6 | Treatment
The ECIL- 6 guideline attributes an A- I recommendation to both vori-
conazole and isavuconazole for the treatment of IA.30 Unfortunately, 
in 2016 surveillance data showed that triazole resistance was pre-
sent in 101 of 784 (12.9%) patients with a positive A. fumigatus cul-
ture.6 These data are based on clinical isolates and it is uncertain 
what fraction of these patients met EORTC/MSG criteria. However, 
the clinical relevance of azole-resistance in patients with an inva-
sive Aspergillus infection was described in a recent multicenter study 
and small case series have reported a very high mortality in patients 
infected with a voriconazole resistant A. fumigatus that received 
initial therapy with voriconazole.5,8 The management of IA in The 
Netherlands in the context of a progressively rising incidence of IA 
caused by azole- resistant A. fumigatus strains is challenging because 
evidence- based data on the most appropriate management of this 
emerging clinical problem are lacking. At the time of the survey, all 
centres start voriconazole when the patient is respiratory and clini-
cally stable while awaiting culture and/or resistance PCR results. 
In a clinically unstable patient, five centres still start voriconazole, 
one centre starts posaconazole and another centre starts L- AmB. 
The feasibility to perform a BAL (and thus cultures) is the decisive 
factor for one centre. In 2015 an international consensus paper on 
the management of IA caused by azole- resistant Aspergillus isolates 
advised L- AmB or echinocandin- voriconazole combination as treat-
ment of choice in regions with environmental triazole resistance 
rates of Aspergillus exceeding 10%.25
Therapeutic drug monitoring was systematically used in four cen-
tres for voriconazole, on indication or not at all in two centres each. 
Although some studies suggest a relation between voriconazole 
serum levels and the incidence of adverse events, randomised clini-
cal trials that convincingly show the value of TDM are still lacking.31
Off- guideline management (as compared with the Dutch guide-
line on fungal infections) was observed in some of the centres.19 One 
common reason for a delay in policy change after new convincing ev-
idence was published and incorporated in guidelines is the absence 
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of a dedicated haematologist with special interest in infectious dis-
eases and supportive haematological care who critically assesses the 
local practice on a regular basis. We asked the centres for the rea-
sons of their off- guideline policies and the following answers were 
given: The continued use of itraconazole instead of posaconazole as 
anti- mould prophylaxis in 2 centres was driven by the higher costs of 
other azoles. Both centres recently moved to voriconazole after it be-
came available as a generic drug. One centre preferred voriconazole 
over posaconazole and this was driven by the unpredictable absorp-
tion of the oral solution and the lack of an intravenous formulation 
of posaconazole when it first came on the market. Another centre 
used nebulised liposomal amphotericin- B as anti- mould prophylaxis 
and did this based on locally generated evidence that supports its 
(cost- )effectivity.21,22 Finally, the continued use of oral amphoteri-
cin- B solution as anti- yeast prophylaxis (on top of fluconazole) was 
driven by the fact that it is a harmless intervention (as no systemic 
toxicity occurs with a non- absorbed drug) and because with this pol-
icy, the incidence of candidaemia had been very low with this policy 
for more than 15 years. Therefore, these centres were reluctant to 
change a safe policy that seems to be very efficacious.
4.7 | Protocol
Following this survey, a consensus meeting was organised with 
representatives of all 8 centres and led to the development of a 
 standardised diagnostic and therapeutic protocol on the management 
of IFD in haematology patients (Figure 1). This protocol was devel-
oped in collaboration with the recently established Dutch- Belgian 
Mycosis Study Group (DB- MSG) and was implemented in all academic 
haematology centres in 2017 with the goal to gather evidence on the 
F IGURE  1 Treatment protocol for Azole-resistance Management- study. MIC, Minimal Inhibitory concentration; IV, Intravenously. 
*Posaconazole HD can only be considered as treatment option when the MIC (EUCAST) ≤1 g/dL. HRCT, High Resolution CT scan; PCR, 
polymerase chain reaction; PO, by mouth; BAL, Broncho- alveolar lavage
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optimal approach towards IFD in the context of azole-resistance (The 
Azole-Resistance MANagement Study (AzoRMan) or DB- MSG 002 
study, NCT03121235). The study aims to demonstrate that the use 
of resistance testing by PCR on BAL fluid from haematology patients 
with suspected IA will lead to an improved outcome by detecting re-
sistance earlier and changing triazole therapy to L- AmB as soon as re-
sistance is detected. Indeed, the majority of cases of IA remain culture 
negative and therefore, the use of resistance testing by PCR is con-
sidered crucial.8,32 The AzoRMan- study is schematically depicted in 
Figure 1 and further information available at www.clinicaltrials.gov. In 
brief, treatment is based on the documentation of azole susceptibility 
or resistance and step- down treatment options for patients treated 
for documented or presumed azole-resistance are given.
Treatment with L- AmB is advised when azole- resistance is doc-
umented or when no susceptibility data are available and the local 
azole- resistance rate is >10%. This is supported by the fact that the 
A. fumigatus strains with the environmental TR34/L98H or the TR46/
Y121F/T289A mutation pattern circulating in the Netherlands remain 
susceptible to L- AmB.33 The activity of L- AmB was also confirmed in 
vivo in immunocompetent and immunosuppressive murine models 
of IA.34 This approach may be less appropriate in different settings 
in which resistance mechanisms other than the environmental TR34/
L98H or the TR46/Y121F/T289A mutation patterns are predominant.
35
If a treatment response is observed during therapy with L- AmB 
3 mg/kg/day, a switch to L- AmB 5 mg/kg/day three times a week or 
to oral posaconazole (when the posaconazole MIC is below 2 mg/L) 
is made with a posaconazole target trough serum level of 3- 4 mg/L. 
The logical behind the posaconazole strategy is the observation 
that Aspergillus strains carrying RAMs often have a posaconazole 
minimum inhibitory concentrations (MIC) that is <2 mg/L.36 The 
efficacy of posaconazole at high serum levels was demonstrated 
in a pharmacodynamic study in mice with invasive azole- resistant 
aspergillosis by Mavridou et al.37 This study showed that posacon-
azole retains activity against an A. fumigatus strain that carried the 
TR34/L98H mutation with a posaconazole MIC of 0.5 mg/L as long 
as serum drug levels are sufficiently high. No human data on the 
use of this treatment strategy have been published. However, in a 
phase 3 pharmacokinetics and safety study for posaconazole tablets 
the average serum concentration of posaconazole in quartile 4 of 
the 186 patients that received posaconazole tablets at 300 mg per 
day was 2.3- 9.5 mg/L. It was not associated with a specific safety 
signal and therefore, a serum level between 3 and 4 mg/L is a realis-
tic target.38 Posaconazole with high serum trough levels is the only 
oral step- down treatment option for patients with azole- resistant 
IA. Although clinical evidence remains anecdotal, preclinical animal 
studies and experience in veterinary medicine provides proof op 
principle in its efficacy.37,39
5  | CONCLUSION
This survey shows the heterogeneous landscape in the prevention, 
diagnosis and treatment of IA in The Netherlands. In the context of 
the rapidly increasing prevalence of azole-resistance, the AzorMan 
study was implemented to evaluate a uniform diagnostic and thera-
peutic approach.
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